Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells

Blood

Volumn 104, Issue 4, 2004, Pages 978-985

  Charrier, Sabine ^b   Michaud, Annie ^b   Badaoui, Sabrina ^b   Giroux, Sébastien ^b   Ezan, Eric ^b   Sainteny, Françoise ^b   Corvol, Pierre ^b   Vainchenker, William ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; TELMISARTAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD TOXICITY; BURST FORMING UNIT E; COLONY FORMING UNIT GM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE COUNT; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION PROTECTION; SURVIVAL; THROMBOCYTE COUNT;

EID: 3843151491     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3828     Document Type: Article

References (34)

1. Grzegorzewski K, Ruscetti FW, Usui N, et al. Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med. 1994;180:1047-1057.
2. Parker AN, Pragnell IB. Inhibitors of haemopoiesis and their potential clinical relevance. Blood Rev. 1995;9:226-233.
3. Guest I, Uetrecht J. Bone marrow stem cell protection from chemotherapy by low-molecular-weight compounds. Exp Hematol. 2001;29:123-137.
4. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96:2022-2036.
5. Soma T, Yu JM, Dunbar CE. Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. Blood. 1996;87:4561-4567.
6. Bonnet D, Lemoine FM, Najman A, Guigon M. Comparison of the inhibitory effect of AcSDKP, TNF-alpha, TGF-beta, and MIP-1 alpha on marrow-purified CD34+ progenitors. Exp Hematol. 1995;23:551-556.
7. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A. 1989;86:779-782.
8. Guigon M, Bonnet D, Lemoine F, et al. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp Hematol. 1990;18:1112-1115.
9. Monpezat JP, Frindel E. Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP, I: the precise point of the cell cycle sensitive to AcSDKP: studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response. Exp Hematol. 1989;17:1077-1080.
10. Jackson JD, Yan Y, Ewel C, Talmadge JE. Activity of acetyl-n-ser-asp-lys- pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Exp Hematol. 1996;24:475-481.
11. Aidoudi S, Guigon M, Drouet V, Caen JP, Han ZC. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo. Int J Hematol. 1998;68:145-155.
12. Masse A, Ramirez LH, Bindoula G, et al. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood. 1998;91:441-449.
13. Rieger KJ, Saez-Servent N, Papet MP, et al. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem J. 1993;296:373-378.
14. Ezan E, Carde P, Le Kerneau J, et al. Pharmacokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis. Drug Metab Dispos. 1994;22:843-848.
15. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
16. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol. 1997;59:395-412.
17. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991;18:100-105.
18. Skidgel RA, Erdos GE. Biochemistry of angiotensin I-converting enzyme. In: Robertson JS, Nicholls MG, eds. The Renin-Angiotensin System. London, United Kingdom: Gower Medical Publishing; 1993:10.1-1.0.10.
19. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
20. Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97:839-844.
21. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension. 1997;30:1015-1019.
22. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin 11 on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18:287-294.
23. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100:2310-2314.
24. Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, et al. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo. Exp Hematol. 1998;26:1074-1079.
25. Chisi JE, Wdzieczak-Bakala J, Thierry J, Briscoe CV, Riches AC. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells. 1999;17:339-344.
26. Chisi JE, Briscoe CV, Ezan E, Genet R, Riches AC, Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br J Haematol. 2000;109:563-570.
27. Junot C, Gonzales MF, Ezan E, et al. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther. 2001;297:606-611.
28. Herodin F, Bourlin P, Mayol JF, Lataillade JJ, Drouet M. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma-irradiation promotes survival. Blood. 2003;101:2609-2616.
29. Mouthon MA, Van der Meeren A, Gaugler MH, et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys. 1999;43:867-875.
30. Geiger H, Van Zant G. The aging of lympho-hematopoietic stem cells. Nat Immunol. 2002;3:329-333.
31. Sudo K, Ema H, Morita Y, Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med. 2000;192:1273-1280.
32. Rodgers KE, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol. 2002;49:403-411.
33. Molteni A, Moulder JE, Cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol. 2000;76:523-532.
34. Moulder JE, Fish BL, Cohen EP. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr Pharm Des. 2003;9:737-749.